Drug-drug interactions of ritonavir-boosted SARS-CoV-2 protease inhibitors in solid organ transplant recipients: experience from the initial use of lopinavir-ritonavir
Clinical Microbiology and Infection · 2023
DOI: 10.1016/j.cmi.2023.01.002 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Clinical Microbiology and Infection, 2023. Verfasst von Ruben Gonzalez-García und 19 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Service, Division of Medicines, Hospital Clínic Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Sp…. Hauptthemen laut MEDLINE: COVID-19, Organ Transplantation. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Gilead Sciences, Genentech.
Abstract (Originalsprache)
OBJECTIVES: To review the drug-drug interactions between tacrolimus and lopinavir/ritonavir in 23 patients who received solid organ transplant during the first wave of COVID-19 and to determine the efficacy as well as safety of prednisone monotherapy. METHODS: Observational study performed between March and June 2020 in solid organ transplant recipients admitted with an established diagnosis of SARS-CoV-2 infection who received lopinavir/ritonavir (≥2 doses). Once lopinavir/ritonavir therapy was initiated, calcineurin inhibitor treatment was temporarily switched to prednisone monotherapy (15-20 mg/d) to avoid drug-drug interactions and toxicity. After lopinavir/ritonavir treatment completion, immunosuppressive treatment was restarted with reduced doses of prednisone-tacrolimus (target minimum blood concentration -C0- approximately 5 ng/mL). Patients were observed for 3 months to confirm the absence of rejection. RESULTS: The median time from discontinuation of tacrolimus to initiation of lopinavir/ritonavir was 14 hours (interquartile range [IQR], 12-15) and from discontinuation of lopinavir/ritonavir to resumption of tacrolimus 58 hours (IQR, 47-81). The duration of lopinavir/ritonavir treatment was 7 days (IQR, 5-7). Nine of the 21 (42.8%) patients on tacrolimus treatment had C0 above the cutoff point after lopinavir/ritonavir initiation, despite having been substituted with prednisone before lopinavir/ritonavir initiation. Three patients had very high concentrations (>40 ng/mL) and developed toxicity. No episodes of acute rejection were diagnosed. DISCUSSION: We did not observe toxicity in patients for whom tacrolimus was discontinued 24 hours before starting lopinavir/ritonavir and reintroduced at half dose 48 to 72 hours after lopinavir/ritonavir discontinuation. Prednisone monotherapy during lopinavir/ritonavir therapy was safe with no episodes of acute rejection. Experience with lopinavir/ritonavir may be applicable to the use of nirmatrelvir/ritonavir, but larger multicentre studies are needed to confirm these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmacy Service, Division of Medicines, Hospital Clínic Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
- Pharmacology and Toxicology Laboratory, Biochemistry and Molecular Genetics Department, Biomedical Diagnostic Center, Hospital Clinic Barcelona, Barcelona, Spain.
- Infectious Diseases Service, Hospital Clínic Barcelona - IDIBAPS, University of Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red. Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spa…
- Infectious Diseases Service, Hospital Clínic Barcelona - IDIBAPS, University of Barcelona, Barcelona, Spain.
- Heart Failure and Heart Transplant Unit, Cardiology Department, Cardiovascular Institute, Hospital Clinic Barcelona - IDIBAPS, Barcelona, Spain.
- Department of Nephrology and kidney Transplantation, Hospital Clínic Barcelona - IDIBAPS, Barcelona, Spain.
Förderung
- Gilead Sciences
- Genentech
Zitieren
APA
Gonzalez-García, R., Roma, J. R., Rodríguez-García, M., Arranz, N., Ambrosioni, J., Bodro, M., Castel, M. Á., Cofan, F., Crespo, G., Diekmann, F., Farrero, M., Forner, A., LLigoña, A., Marcos, M. Á., Moreno, A., Ruiz, P., Soy, D., Brunet, M., Miró, J. M., & Tuset, M. (2023). Drug-drug interactions of ritonavir-boosted SARS-CoV-2 protease inhibitors in solid organ transplant recipients: experience from the initial use of lopinavir-ritonavir. Clinical Microbiology and Infection. https://doi.org/10.1016/j.cmi.2023.01.002
Vancouver
Gonzalez-García R, Roma JR, Rodríguez-García M, Arranz N, Ambrosioni J, Bodro M, et al. Drug-drug interactions of ritonavir-boosted SARS-CoV-2 protease inhibitors in solid organ transplant recipients: experience from the initial use of lopinavir-ritonavir. Clinical Microbiology and Infection. 2023. doi:10.1016/j.cmi.2023.01.002
BibTeX
@article{GonzalezGarca2023,
author = {Gonzalez-García, Ruben and Roma, Joan-Ramon and Rodríguez-García, María and Arranz, Natalia and Ambrosioni, Juan and Bodro, Marta and Castel, Maria-Ángeles and Cofan, Federic and Crespo, Gonzalo and Diekmann, Fritz and Farrero, Marta and Forner, Alejandro and LLigoña, Ana and Marcos, Maria Ángeles and Moreno, Asunción and Ruiz, Pablo and Soy, Dolors and Brunet, Mercè and Miró, Jose M and Tuset, Montse},
title = {Drug-drug interactions of ritonavir-boosted SARS-CoV-2 protease inhibitors in solid organ transplant recipients: experience from the initial use of lopinavir-ritonavir},
journal = {Clinical Microbiology and Infection},
year = {2023},
doi = {10.1016/j.cmi.2023.01.002}
}
EUVIMED